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Tumor metastasis is a major contributor to the death of cancer patients. It is driven not only by the intrinsic
alterations in tumor cells, but also by the implicated cross-talk between cancer cells and their altered
microenvironment components. Tumor-associated macrophages (TAMs) are the key cells that create an
immunosuppressive tumor microenvironment (TME) by producing cytokines, chemokines, growth factors, and
triggering the inhibitory immune checkpoint proteins release in T cells. In doing so, TAMs exhibit important
functions in facilitating a metastatic cascade of cancer cells and, meanwhile, provide multiple targets of certain
checkpoint blockade immunotherapies for opposing tumor progression. In this article, we summarize the regulating
networks of TAM polarization and the mechanisms underlying TAM-facilitated metastasis. Based on the overview of
current experimental evidence dissecting the critical roles of TAMs in tumor metastasis, we discuss and prospect
the potential applications of TAM-focused therapeutic strategies in clinical cancer treatment at present and in the
future.
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Metastasis is a process of tumor cells escaping from the
primary sites, spreading through lymphatic and/or blood
circulations and ultimately disseminating to the distant
sites. As one of the hallmarks of cancer, development of
metastasis accounts for more than 90% cancer-related
deaths [1]. Usually, the metastasis of tumor cells is a
multistep sequence mainly including (a) invasion in the
primary sites, (b) intravasation into the vasculature, (c)
survival in the circulations, (d) extravasation out of the
vasculature, and (e) adaption and growth in the meta-
static sites [2, 3]. Failure in any of those steps will pre-
vent the formation of metastasis. In addition to the
alterations of the intrinsic properties in tumor cells, the
“seed and soil” concept, firstly proposed by Stephen
Paget in 1889, has been widely accepted as a critical the-
ory to do with metastasis [4]. In this theory, tumor cells© The Author(s). 2019 Open Access This artic
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tastasis. In fact, both the tumor cells and multiple com-
ponents of the tumor microenvironment (TME) and
their complicated cross talk are closely involved [5, 6].
Macrophages populating in the surrounding TME are
usually termed as tumor-associated macrophages
(TAMs) [7, 8]. A large volume of studies suggests that
TAMs serve as prominent metastasis promoters in the
TME, which orchestrate almost all of the 5 cascade steps
of tumor metastasis as mentioned above [9, 10]. By pro-
ducing growth factors, proteolytic enzymes, and various
inhibitory immune checkpoint proteins in T cells, TAMs
display implicated functions in regulating metastasis.
Also, targeting TAMs as therapeutic strategies to pre-
vent tumor progression and metastasis has attracted
more and more researchers’ attention in recent years. So
far, different types of molecular agents against TAMs are
emerging as potential anti-cancer approaches. This re-
view aims to provide an overview of the origin, classifi-
cation, and polarization of TAMs as well as the
mechanisms underlying the TAM-induced metastasis.
Also, we will specifically discuss the agents targetingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Lin et al. Journal of Hematology & Oncology           (2019) 12:76 Page 2 of 16TAMs for cancer therapy. It is hoped that this review
will help readers to understand the roles of TAMs in
metastasis and their potential in clinic therapeutic appli-
cations against tumor progression.Overview: biological information and polarization
of TAMs
The definition, origin, and functions of TAMs
Macrophages are a type of versatile immunocytes, exe-
cuting a broad spectrum of functions that range from
modulating tissue homeostasis, defensing against patho-
gens, and facilitating wound healing [11]. Macrophages
infiltrating tumor tissues or populated in the microenvir-
onment of solid tumors are defined as tumor-associated
macrophages (TAMs). As a critical component of tumor
microenvironment, TAMs affect tumor growth, tumor
angiogenesis, immune regulation, metastasis, and che-
moresistance. Most of the TAMs gather in the leading
edge and avascular areas, while some others align along
the abluminal side of the vessels as well [12, 13]. It is
generally believed that the blood monocytes derived
from bone marrow hematopoietic stem cells are the pri-
mary resource of macrophages [14–16]. However, recent
evidence suggests that a majority of resident macro-
phages stem from yolk sac progenitors, which proliferate
or differentiate in situ and have progeny throughout
their life, such as alveolar macrophages, brain macro-
phages, and Kupffer cells [11, 17–19]. They are recruited
and activated by various signals in the TME and then ex-
hibit dramatic impacts on the tumor progression andFig. 1 Cellular origins and functions of TAMs. As the major primary resourc
cells (HSCs) that differentiate into granulocyte-macrophage progenitors (GM
Besides, tissue-resident macrophage stem from yolk sac progenitors are an
in situ, such as alveolar macrophages, brain macrophages, and Kupffer cells
macrophages are recruited and activated by various signals in the TME and
metastasis, immune regulation and angiogenesismetastasis. The cellular origin of macrophages and
TAMs was shown in Fig. 1.
Like macrophages perform diverse functions in im-
mune regulation, TAMs also play multi-functional roles
in tumor progression, including cancer initiation and
promotion, immune regulation, metastasis, and angio-
genesis, as shown in Fig. 1. For example, the presence of
TAM-derived inflammatory cytokines interleukin (IL)-23
and IL-17 have been shown to trigger tumor-elicited in-
flammation, which in turn drives tumor growth [20]
(Fig. 1). Another study demonstrated that the increased
TAM-derived IL-6 exerts an amplifying effect on the in-
flammation response, thus promoting the occurrence
and development of hepatocellular carcinoma via STAT3
signaling [21]. Moreover, TAMs acquire an M2-like
phenotype, providing essential support on tumor pro-
gression and metastasis, despite their weak antigen pre-
senting ability [22].
The classification and polarization of TAMs
It is clear that macrophages are capable of displaying
very different and even opposing phenotypes, depending
on the microenvironment they embedded in. Activated
macrophages are often classified into M1 (classical-acti-
vated macrophages) and M2 (alternative-activated mac-
rophages) phenotype [23] (Fig. 2). In general, M1
macrophages foster inflammation response against in-
vading pathogens and tumor cells, whereas M2 macro-
phages tend to exert an immune suppressive phenotype,
favoring tissue repair and tumor progression. These two
types of macrophages are distinct in their differente of macrophages, monocytes are generated from hematopoietic stem
Ps) and then into monocyte-dendritic cell progenitors (MDPs).
other key resources of macrophages, which proliferate or differentiate
. The mature monocytes released in the blood and tissue-resident
then exhibit dramatic impacts on the tumor initiation and promotion,
Fig. 2 Tumor-associated macrophages (TAMs) polarization and its regulatory networks. Polarization of TAMs is regulated by multiple
microenvironmental cytokines, growth factors, epigenetic regulators, and other signals derived from tumor and stromal cells. Two types of
macrophages (M1/M2) secrete different immune markers, metabolic characteristics, and gene expression profiles to exert different functions
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profiles. M1 macrophages secrete proinflammatory cyto-
kines such as IL-12, tumor necrosis factor (TNF)-α,
CXCL-10, and interferon (IFN)-γ and produce high
levels of nitric oxide synthase (NOS, an enzyme metab-
olizing arginine to the “killer” molecule nitric oxide),
while M2 macrophages secrete anti-inflammatory cyto-
kines such as IL-10, IL-13, and IL-4 and express abun-
dant arginase-1, mannose receptor (MR, CD206), and
scavenger receptors [24, 25] (Fig. 2). The conversion be-
tween M1 (anti-tumorigenesis) and M2 (pro-tumorigen-
esis) is a biological process named “macrophage
polarization” in response to microenvironmental signals
[26]. Though studies found that TAMs are able to ex-
hibit either polarization phenotype, researchers tend to
consider TAMs as M2-like phenotype-acquired macro-
phages [22, 26–28]. It is consistent with these clinical
observations that the accumulation of macrophages in
the TME is largely associated with worse disease out-
come [13, 29]. However, classification and identification
of TAMs should be correlated mainly to their function
such as metastasis, angiogenesis, and immune regula-
tion. Expression of CD68, CD14, HLA-DR, and CD204
have been used for macrophage classification, and other
proteins such as MMP2/9, B7-H4, STAT-3, CD163, and
CD206 have been used for classification of TAMs [30].
We have listed these characterized biomarkers, CDs, andcytokines for TAM identification in Table 1. To better
understand the correlation between TAMs, metastasis,
and clinical applications in cancer therapy, we will fur-
ther characterize the molecular mechanisms underlying
TAMs polarization from M1-like to M2-like in detail
below, also as shown in Fig. 2.
Polarization of TAMs is regulated by multiple micro-
environmental cytokines, chemokines, growth factors,
and other signals derived from tumor and stromal cells
[24]. Among those factors, colony stimulating factor 1
(CSF-1) and C-C motif ligand 2 (CCL2) are the most
two well-documented macrophage recruiters and M2-
stimulating factors (Fig. 2). CCL2 was earlier reported to
shape macrophage polarization toward the protumor
phenotype via the C-C chemokine receptor 2 (CCR2)
expressed on the surface of macrophages [38]. Blocking
the CCL2-CCR2 interaction either by genetic ablation or
antibodies obviously inhibits metastatic seeding and pro-
longs the survival of tumor-bearing mice along with the
diminished protumor cytokine expression [38–40].
Moreover, abundant clinicopathological data have veri-
fied the association between high concentrations of
CCL2 in tumor with increased TAM infiltration and
metastatic events [22, 39, 41]. CSF-1 is another potent
determinant factor of macrophage polarization. CSF-1
wide overexpression is observed at the invasive edge of
various tumors and correlates with a significant increase
Table 1 Biomarkers associated with tumor-associated macrophages
Characteristics Function Expression Detection Ref.
M1 M2 In situ In vitro
Biomarkers MMP2/9 Matrix metalloproteinase − + IHC Digestion [31]
B7-H4 Inhibiting costimulatory molecule − + IHC Flowcytometry [32]
STAT-3 Transcription factor − + IHC Flowcytometry [33]
iNOS Nitric oxide synthase + − IHC N/A [34]
HLA-DR Antigen presentation molecule + + IHC Flowcytometry [35]
CDs CD68 Glycoprotein for adherence + + IHC Flowcytometry [30]
CD14 LPS co-receptor + + IHC Flowcytometry [30]
CD163 Scavenger receptor hemoglobulin − ++ IHC Flowcytometry [30]
CD206 Mannose receptor + ++ N/A Flowcytometry [30]
CD204 Macrophage scavenger receptor 1 + + IHC N/A [36]
Cytokines IL-12p70 Interleukin ++ − IHC ELISA [37]
IL-10 Interleukin + ++ IHC ELISA [37]
Marked with “−”: no expression; “+”: present on cell subset; “++”: highly expressed or produced
IHC immunohistochemical staining
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showed that CSF-1 depletion led to greatly reduced
macrophage density, delayed tumor progression, and se-
verely inhibited metastasis [22, 24, 42, 43]. And the res-
toration of expression of CSF-1 in CSF-1 null mutant
mice with xenografts accelerated both tumor progres-
sion and metastasis [42]. Vascular endothelial growth
factor A (VEGF-A) has long been considered as a
powerful pro-tumor factor [44]. Other than its pro-
angiogenic effects, VEGF-A also fosters the malignant
growth of tumors by inducing TAM infiltration and M2
polarization in the presence of IL-4 and IL-10 [45]. Dir-
ect evidence came from the gain-of-function experi-
ments in the xenograft model of skin cancer, whereby
VEGF-A upregulation rescued the clodronate induced
macrophage depletion and resulted in shortened xeno-
graft survival [45–47]. Besides, the overactivation of the
epidermal growth factor receptor (EGFR) signaling path-
way by either overexpression or mutation is frequently
involved in tumor initiation, growth, and metastasis [48].
Actually, EGFR signaling not only promotes proliferation
and invasiveness of tumor cells directly, but also adjusts
the TME by regulating macrophage recruitment and
M2-like polarization [49, 50]. Disrupted EGFR signaling
by cetuximab or gene knockout resulted in less M2-
polarized TAMs and correlated with better prognosis in
colon cancer models of mice [51, 52]. Beyond those
well-investigated factors mentioned above, a number of
new homeostatic factors have been described as TAM
inducers recently. For example, prostaglandin E2 (PGE2)
synergized with CSF-1 to promote M2 polarization by
transactivating the CSF-1R, and PGE2-elicited macro-
phage infiltration was significantly halted in the absence
of CSF-1R [53]. In addition, CCN3 (also known as NOV,nephroblastoma overexpressed) led to enhanced M2
macrophage infiltration, whereas CCN3 deficiency pro-
longed xenograft survival in prostate cancer [54]. Fur-
thermore, other chemokines such as IL-4, IL-6, IL-13,
CCL7, CCL8, CCL9, CCL18, and CXCL12 are also
highly expressed in tumors and involved in TAM re-
cruitment and polarization [9, 10, 55–57] (Fig. 2).
Hypoxia, which resulted from tumor cells with a status
of vigorous metabolism and rapid growth but poorly or-
ganized vasculature, is a common feature occurring in
the majority of solid tumors [58]. Hypoxia promotes the
malignant tumor behaviors by various mechanisms, such
as inducing immune escape, promoting glycolysis, antag-
onizing apoptosis, promoting cell dedifferentiation, and
reducing therapeutic effectiveness [59–61]. It is worth
noting here that hypoxia also roles as a vital regulator of
macrophages, which helps tumor cells overcome nutri-
tive deprivation and convert the TME into more hospit-
able sites [28]. The gradients of chemokines induced by
hypoxia, such as CCL2, CCL5, CSF-1, VEGF, semaphorin
3A (SEMA3A), endothelial cell monocyte-activating
polypeptide-II (EMAP-II), endothelin, stromal cell-
derived factor 1α (SDF1α), eotaxin, and oncostatin M,
are responsible for the migration of TAMs into the hyp-
oxic areas [28]. Hypoxia further traps the seeding mac-
rophages by downregulating the chemokine receptors
expressed on macrophages [62, 63]. Besides, hypoxia
modulates the TAM phenotype toward a pro-tumoral
profile by various factors. Lactate, massively produced
by anaerobic glycolysis of tumor cells in oxygen-
deprived areas, is one of the key inducers of M2 pheno-
type. It can be sensed by G protein-coupled receptor
132 (Gpr132), a membrane receptor on macrophages,
which subsequently activates downstream signals and
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genes [64]. And it has been shown that the enhanced ex-
pression of Gpr132 relates to the worse outcome of
breast cancer patients, which was further verified by the
positive association between the Gpr132 level and M2
macrophages infiltration, metastasis, and poor prognosis
in breast cancer models in mice [64]. Similar stimulatory
functions on macrophage accumulation and polarization
can also be achieved by angiopoietin-2 (Ang-2), which is
generally accepted as a regulator of vessel stabilization
and growth in accompany with VEGF, Ang-1, via specif-
ically binding to the receptor Tie-2 [65, 66] (Fig. 2).
Ang-2 can also be dramatically upregulated by hypoxia
[65]. However, there exists opposed evidence claiming
that hypoxia is not the major driver of M1-M2 skewing
[28, 67]. Instead of a direct effect on M2 transforming,
hypoxia only fine-tunes hypoxia-regulated genes expres-
sion without influencing their M2 markers expression or
the relative abundance of TAM subsets [67].
Epigenetic derangements is another universal feature
in cancer. Epigenetic regulators reshape chromatin
structures, pack the genome, and change gene expres-
sion patterns without altering the genome itself [68, 69].
More recently, a growing number of publications focus
on the epigenetic participation in macrophage pheno-
typic switch [70, 71] (Fig. 2). Usually, most of the key
points of epigenetic regulators are enzymes, which are
druggable and easy to be translated into clinical applica-
tions for tumor intervention. For example, protein argin-
ine methyltransferase 1 (PRMT1), SET and MYND
domain-containing protein 3 (SMYD3), Jumonji
domain-containing protein 3 (JMJD3), NAD-dependent
protein deacetylase sirtuin-2 (SIRT), and bromodomain
and extraterminal (BET) proteins positively regulate M2
polarization by upregulating M2 markers, while DNA
methyltransferase 3b (DNMT3b), Jumonji domain-
containing protein 1A (JMJD1A), histone deacetylase 3
(HDAC3), and HDAC 9 do the opposite effect [70, 71].
Interfering these epigenetic enzymes with pharmacologic
modulators was able to prevent these macrophages from
polarizing to M2 s and control the malignant progres-
sion of tumors.
As another type of epigenetic regulator, microRNAs
(miRNAs) are also in control of macrophage polarization
(Fig. 2). To date, miR-125, miR-155, miR-378, miR-9,
miR-21, miR-146, miR-147, miR-187, miR-222, and miR-
let7b have been reported as dominant TAM modulators
[72]. For example, miR-222-3p, implicated as a tumor
promoter in diverse tumor types, activates macrophages
to the M2 phenotype by downregulating suppressor of
cytokine signaling-3 (SOCS3) which is a negative feed-
back regulator of the JAK/STAT signaling pathway [73].
What is more, let-7b, enriched in prostatic TAMs, is
drawing attention along the same line. Prostatic TAMstreated with let-7b inhibitors displayed characteristics of
M1, with a significantly higher expression of pro-
inflammatory cytokines (such as IL-10, IL-12, and IL-
23), and downregulated pro-tumoral cytokines such as
TNF-α [74].
Taken together, the polarization of TAMs is regulated
by complicated biological networks (Fig. 2), which clinic-
ally correlates with cancer metastasis and progression.
Mechanisms underlying TAM-facilitated
metastasis
As mentioned above, TAMs display lots of important
biological functions in tumor progression from different
aspects. Here, we mainly focus on the correlation be-
tween TAMs and tumor metastasis. In fact, how TAMs
contribute to tumor metastasis is a puzzling question
which enables researchers to pursue the answers for
dozens of years, though the existing studies demonstrate
that TAMs implicate in almost every step of metastasis
as described below, also shown in Fig. 3.
TAMs promote invasion of tumor cells
Metastasis begins with tumor cells obtaining the ability
of invasiveness and escaping from the confines of the
basement membrane into the surrounding stroma [5,
75]. Highly invasive tumor cells always share the charac-
teristics of loss of intrinsic polarity and loosely attach-
ment to the surrounding tissue structures [76].
Epithelial-mesenchymal transition (EMT) is a predomin-
ant event in this morphological transformation, which
contributes to malignant biological properties including
invasion and metastasis [76]. During EMT process,
tumor cells lose cell-cell junctions and apical-basal po-
larity as a result of E-cadherin repression and acquire a
motile mesenchymal cell phenotype [77, 78].
Recently, a number of studies suggested that TAMs in-
volve in the regulation of EMT process [79–81]. Immu-
nostaining of clinical hepatocellular carcinoma (HC)
samples revealed that the EMT hotpots, such as the edge
of tumor nests, are also the sites where TAMs infiltrate
in abundance [80]. Moreover, co-cultured HC cell lines
with TAMs enhanced the expression of N-cadherin and
Snail, both of which are hallmarks of mesenchymal phe-
notypes. Meanwhile, E-cadherin was observed to be
downregulated. This phenomena also occurred in gastric
cancer and pancreatic ductal adenocarcinoma (PDAC)
[82]. Biologically, macrophages participate in the EMT
process via secreting various soluble factors, such as IL-
1β, IL-8, TNF-α, and transforming growth factor-β
(TGF-β) [80, 83, 84]. Extracellular matrix (ECM) serves
as a scaffold as well as a barrier for tumor cell migration
[85], of which degradation is a focal event in metastasis.
It has been identified that TAMs are capable of secreting
a number of proteolytic enzymes, including cathepsins,
Fig. 3 Mechanisms of tumor-associated macrophages (TAMs) in tumor metastasis. TAMs affect virtually almost every step of tumor cells
metastasis, including invasion, vascularization, intravasation, extravasation, establishing pre-metastatic niches, and protecting circulating tumor
cells survival
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MMP2, and MMP9), and serine proteases, which are im-
portant components mediating ECM degradation and
cell-ECM interactions [86–88]. In addition, an earlier
study demonstrated that M2 macrophage promotes the
invasiveness of gastric and breast cancer cells by produ-
cing chitinase 3-like protein 1 (CHI3L1). CHI3L1 upre-
gulates MMP expression via interacting with
interleukin-13 receptor α2 (IL-13Rα2) chain which trig-
gers the activation of the mitogen-activated protein kin-
ase (MAPK) signaling pathway [89]. Once the tumor
cells break away from the constraint of ECM networks,
they would move toward the stimuli along with the
ECM fiber by interacting with other ECM components,
such as fibronectin and vitronectin [90, 91]. Further-
more, secreted protein acidic and rich in cysteine
(SPARC) synthesized by TAMs were shown to be neces-
sary for the migration of tumor cells, aside from its role
as an ECM deposition regulator. According to the earlier
studies, SPARC favors fibronectin and vitronectin inter-
action with tumor cells through integrins, generating a
traction force along ECM fibers [92, 93]. The traction
force pulls tumor cells to rapidly travel through the
stroma like tram lines and guarantees the rapid motiv-
ation of cells within stroma as well as toward tumor vas-
culature since many of those ECM fibers terminally
converge on blood vessels [90]. Genetic ablation ofSPARC led to attenuated metastasis by decreased ECM
deposition and impaired tumor cell-ECM interaction
[90, 92, 93].
TAMs promote vascularization of tumor cells
Tumor vasculature serves as a major route for the me-
tastasis of malignant tumors. When solid tumors grow
up to a certain size, a process termed as “ angiogenic
switch” will be turned on by various mechanisms to trig-
ger a high-density vasculature for nutrients supply and
wastes removal [94, 95]. TAMs are critical players in the
regulation of “angiogenic switch.” They form clusters in
the intra-tumoral regions and the invasive fronts, both
of which are the hotspots of angiogenesis and metastasis.
In contrast, the absence of TAMs significantly reduced
the vessel density by 40% [96, 97]. In addition to affect-
ing the formation of new tumor vessels, TAMs also
stimulate the remodeling of the established vasculature
to a more tortuous and leaky form in favor of tumor dis-
semination [96, 97]. In fact, researches strongly argue
the important roles for VEGF and MMP-9 (plays a char-
acter in releasing VEGF from matrix) in regulating
TAM-driven angiogenesis. Also, there are some other
proangiogenic molecules involved as well, such as fibro-
blast growth factor (FGF)-2, CXCL8, IL-1, IL-8, cycloox-
ygenase (COX)-2, nitric oxides (iNOS), and MMP7 [96–
99]. Furthermore, there is a novel subset of TAMs
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known as angiopoietin-1 receptor) termed as TEMs [65,
100]. Experiments in a variety of tumor models clarify
that TEMs were endowed with dramatic proangiogenic
activity, since Tie-2 is capable of binding with all the
known angiopoietins (Angs, including Ang-1, Ang-2,
Ang-3, and Ang-4) [12, 65, 66]. Therefore, selective
elimination of TEMs by a suicide gene strategy may be
another promising option for preventing angiogenesis
and tumor progression [66].
Besides, TAMs also account for lymphangiogenesis, an
important route for tumor cells disseminating to re-
gional lymph nodes and distant metastasis, in a VEGF-C
(a ligand overexpressed by tumors)/VEGFR-3 (a receptor
of VEGF-C expressed on the TAMs) axis-dependent
manner. VEGF-C/VEGFR-3 axis fosters lymph angiogen-
esis either by directly affecting the lymphatic endothelial
cells (LECs) activity or indirectly elevating the cathepsins
secretion whose downstream molecular heparanase is a
robust inducer of lymphangiogenesis [101–103]. From
the mouse models, treatment with antibodies against
VEGF-C/VEGFR-3 or genetic ablation of heparanase sig-
nificantly altered the lymphatic vessel phenotype and
subsequently impaired the primary tumor growth and
metastasis [101].
Taken together, these evidences demonstrate that
TAMs function in the way of promoting the
vascularization of tumors via different pathways and
thus are closely involved in tumor metastasis.
TAMs promote intravasation of tumor cells
Tumor cells squeezing through small pores in vascular
endothelium to gain access to the host vasculature is an-
other critical step in metastasis [104]. An experiment
utilizing intravital multiphoton imaging gave a direct
and kinetical visualization of intravasation. According to
this experiment, an intravasating tumor cell is always vi-
sualized to be accompanied by a macrophage within one
cell diameter, showing a direct evidence of TAMs involv-
ing in tumor cell intravasation [105, 106]. Consistently,
clinical observations have identified the tripartite ar-
rangement of TAMs, tumor cells, and endothelial cells
as the tumor microenvironment of metastasis (TMEM).
The TMEM is a predictor of increased hematogenous
metastasis and poor prognosis, at least in breast cancer
[107]. The mechanisms underlying this synergistic inter-
action are complicated. On the one hand, macrophages
break down the ECM around the endothelium by a
number of proteolytic enzymes such as cathepsins,
matrix metalloproteinases, and serine proteases [86–88].
On the other hand, TAMs hijack tumor cells into the
circulation by a positive feedback loop consisting of
tumor cell-produced CSF-1 and TAM-produced EGF
[108]. The former cytokine stimulates macrophage’smotility as well as EGF production, which in turn signals
to tumor cells and mediates chemotactic migration to-
ward blood vessels [108, 109]. Therefore, inhibition of
either CSF-1 or EGF signaling pathway perturbs the mi-
gration of both cell types and reduces the numbers of
circulating tumor cells as well.
TAMs promote tumor cell survival in the circulation
Once penetrated into the vasculature, the tumor cells
have to be primed for survival and egress from the circu-
lation. Clots packed around the tumor cells alleviate sur-
vival stress from such as natural killer (NK) cells in a
tissue factor (TF)-dependent manner in the general cir-
culation and capillaries [110, 111]. In fact, a strategy dis-
rupting macrophage functions by genetic methods
diminished the tumor cells survival in pulmonary capil-
laries and abrogated tumor invasion into the lung, des-
pite clot formation, indicating an essential role of
macrophages in this aspect [112]. Two plausible mecha-
nisms might account for this phenomenon. In part, a re-
cent study discovered that the recruited macrophages
triggered the PI3K/Akt survival signaling pathway in
newly disseminated breast cancer cells by engaging vas-
cular cell adhesion molecule-1 (VCAM-1) via α4 integ-
rins [113, 114]. The activation of the PI3K/Akt survival
pathway subsequently saved cancer cells from proapop-
totic cytokines such as TNF-related apoptosis-inducing
ligand (TRAIL) [113]. In another part, many of the
tumor cells survive which are protected by macrophages
due to their secreted chemokines or cytokines directly
secreted [112].
TAMs promote extravasation of tumor cells
Once the tumor cells settle in the capillaries of the tar-
geted organs, they would try to attach and extrude
through the vessel walls with the assistant of macro-
phages. The intimate contacts between tumor cells and
macrophages during extravasation were visualized and
quantitatively analyzed within an intact lung imaging
system [115]. Of particular importance, the researchers
found that the extravasation rate was dramatically de-
clined after the loss of macrophages together with a co-
incident failure of metastasis [115].
TAMs prepare sites for tumor cells: pre-metastatic niches
(PMN)
It is believed that metastasis is not necessary to be a late
event in tumor progression [116]. The primary tumors
are smart enough to “prime” the secondary organs and
dictate organ-specific dissemination before the arrival of
tumor cells. Those “primed” sites are predisposed to me-
tastasis and introduced as the concept of pre-metastatic
niches (PMNs) [116]. Studies clarified that macrophages
were one of the key determinants for the formation of
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then clustered in the pre-metastatic sites by a variety of
tumor-secreted factors, such as CCL2, CSF-1, VEGF,
PLGF, TNF-α, TGF-β, tissue inhibitor of metallopepti-
dase (TIMP)-1, and exosomes [116–118]. Besides, the
tissue-resident macrophages, such as liver Kupffer cells,
pulmonary alveolar macrophages, and osteoclasts, were
also involved in orchestrating PMN formation upon
stimulation [119, 120]. The presence of those macro-
phages provide a road map for the homing of circulating
tumor cells (CTCs) into the PMNs with enhanced ex-
pression of chemokines such as stromal derived factor
(SDF)-1 and Ang-1 and remodel the ECM to the tumor
cell-favoring direction by secreting ECM-shaping en-
zymes like MMPs, integrins, and lysyl oxidase (LOX),
most of which have been mentioned above as critical in-
ducers of angiogenesis, EMT, and extravasation [118–
121]. Furthermore, macrophages also establish metabolic
cross talk with immune cells like T helper 1 (TH1) cells
and dendritic cells and attenuate their tumoricidal and
tumor antigen-presenting behaviors, ultimately promot-
ing the prosperity of those newly lodged tumor cells in a
way of immunosuppression.
Potential strategies targeting macrophages
Cancer is one of the most life-threatening diseases as a
major public health problem with extremely high inci-
dence and mortality all over the world. The progression
in anti-tumor research never stops. While most of the
therapeutic approaches nowadays mainly focus on ma-
lignant cells themselves, only limited efficiency has been
achieved. However, in-depth knowledge of the cross talk
between tumor cells and TME has reoriented our ap-
proaches to strategies against pro-metastatic non-tumor
components in the TME. As described above, TAMs are
one of the most essential accessory cells promoting the
tumor progression and metastasis by various mecha-
nisms. More importantly, TAMs are subject to the regu-
lation of complicated molecular signals/factors,
including lots of druggable enzymes and immune check-
point proteins. As such, therapeutic approaches target-
ing TAMs are anticipated to be feasible and promising.
Overall, the TAM-targeted therapeutic solutions would
mainly focus on strategies to eliminate TAMs, impairing
macrophages infiltration and suppressing phenotype
conversion of M2 from M1 [82]. Next, we will discuss
the current agents based on different mechanisms in-
cluding inhibiting TAMs survival, suppressing M2
polarization and inhibiting macrophages recruitment as
below, and we list these related agents in Table 2.
Agents against TAMs survival
Trabectedin is an agent with such cytotoxic efficacy to
TAMs in TME; it has been approved for the treatmentof patients with soft tissue sarcoma in Europe [136].
And it is also under clinical evaluation for other cancer
types, including breast, prostate, and ovarian cancer
[136]. Specifically, trabectedin is accepted as the cyto-
toxic agent directly killing tumor cells by interfering
with several transcription factors, DNA-binding pro-
teins, and DNA repair pathways [137]. Besides, its effects
on the tumor microenvironment by selective mono-
nuclear phagocyte depletion has been claimed as another
key component of its antitumor activity [136]. Mechan-
ically, trabectedin selectively induces rapid apoptosis in
macrophages via TRAIL receptors and blocks their pro-
duction of some pro-metastatic cytokines like CCL2,
CXCL8, IL-6, and VEGF [136, 138]. The pro-apoptotic
efficiency of trabectedin has been evaluated in a pro-
spective study in which 56% (19 in 34) of soft tissue sar-
coma patients experienced monocyte reduction with the
extent ranging from 30~77% [136, 138]. Likewise, lurbi-
nectedin (PM01183) is another novel anticancer agent
structurally related to trabectedin. It functions by both
directly killing tumor cells and affecting TAM-based
immunomodulation [139]. As an analog of trabectedin,
lurbinectedin exhibits potent apoptotic capacity upon
macrophages, and by doing so, it dramatically decreases
the number of macrophages both in circulation and
TME in mice models [139]. Moreover, in the cancer cells
resistant to chemotherapeutic agents, angiogenesis and
distant dissemination were impaired due to
lurbinectedin-caused macrophage depletion [139]. For
clinical trials, various types of solid tumors in different
programs are being conducted to evaluate the clinical
benefits of lurbinectedin [122–124, 140–142]. However,
both trabectedin and lurbinectedin cannot avoid the side
effects arisen by unselectively macrophage consumption
since macrophages closely participated in host defense
and homeostatic regulation [140]. Thus, developing
agents preferentially targeting M2-like macrophages is
the “Holy Grail” to minimize potential toxic side effects.
M2 macrophage-targeting peptide (M2pep), just as im-
plied by the name, is such a construct discovered re-
cently [143]. Researchers found that M2pep was able to
exert selective toxicity to both tumor cells and M2 mac-
rophages without influence on M1 macrophages both
in vitro and in mice models [144, 145]. Based on these
studies, M2pep has been turned out to be a promising
adjuvant strategy for anticancer therapies, though it is
still in the initial stage and needs a long way to go for
substantial clinical applications.
Agents suppressing M2 polarization and enhancing M1
activity of macrophages
As described above, it is widely believed that M2 and
M1 macrophages play opposite roles in tumor growth
and metastasis. Therefore, proposing therapeutic
Table 2 Clinical trials of agents targeting TAMs for cancer treatment
Compound Target Combination partner Tumor type Phase Status/results Ref. or trial no.
Agents that inhibit TAM survival
Trabectedin Pan-macrophages Durvalumab Solid tumors 1 Not yet recruiting NCT03496519
Monotherapy Mesothelioma 2 Recruiting NCT02194231
Lurbinectedin (PM01183) Pan-macrophages Monotherapy Solid tumors 1 No clinical consequences [122]
Monotherapy Ovarian cancer 1 Active, not recruiting [123]




Agents that polarize TAMs to M1 type
Zoledronic acid (ZA) N/A Monotherapy Breast cancer 3 Prolonged survival [125]
Monotherapy Breast cancer 2 Recruiting NCT02347163
CP-870, 893 CD40 Monotherapy Solid tumors 1 PR, 14% [126]




Agents that inhibit TAM recruitment




Monotherapy Dt-GCT 1 CR + PR, 86%
SD, 11%
[129]
Atezolizumab Solid tumors 1 Recruiting NCT02323191
Paclitaxel Ovarian cancer
Breast cancer
1 Not yet reported NCT01494688
Paclitaxel Ovarian cancer 2 Active, not recruiting NCT02923739








Monotherapy Melanoma 1/2 Active, not recruiting NCT02975700
Monotherapy Dt-GCT
GCT-TS
3 Active, not recruiting NCT02371369
ARRY-382 CSF-1R Monotherapy Solid tumors 1 ORR, 0%
SD, 15%
[131]
Pembrolizumab Solid tumors 1b/2 Recruiting NCT02880371
CCX872 CCR2 FOLFIRINOX Pancreatic cancer 1b 18 m OS, 29% [132, 133]
PF-04136309 CCR2 FOLFIRINOX Pancreatic cancer 1b ORR, 49% [134]
Carlumab CCL2 Monotherapy Solid tumors 1b Antitumor activity [135]
Monotherapy Prostate cancer 2 No antitumor activity [135]
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into tumoricidal M1 phenotype and thus inhibiting
TAMs’ supportive roles in tumors is feasible [146]. Zole-
dronic acid (ZA) is an eligible agent of this kind, which
has been FDA-approved as the third generation of
amino-bisphosphonate agent for treating skeletal-related
events (SREs) and pain caused by bone metastasis. Be-
yond the skeleton, plenty of studies have generated newinsights into its potent role in modulating macrophages
phenotypes [147]. According to those studies, ZA was
able to reverse the polarity of TAMs from M2-like to
M1-like by attenuating IL-10, VEGF, and MMP-9 pro-
duction and recovering iNOS expression [99, 148]. Fur-
thermore, ZA was also capable of reducing the total
number of macrophages in the TME by halting TAM re-
cruitment and infiltration [149]. Based on this evidence,
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therapy for premenopausal women with early-stage breast
cancer in ABCSG-12 trial [125]. Data of 62months’ follow-
up [125] showed that the addition of ZA at clinically
achievable doses delayed tumor recurrence and significantly
prolonged disease-free survival, which provides a solid clin-
ical evidence for ZA to be a promising agent for cancer pre-
vention [147, 148]. Another agent capable of repolarizing
TAMs to M1 phenotype is CP-870,893, which is an agonist
monoclonal antibody (mAb) of CD40 [150, 151]. CD40 be-
longs to the tumor necrosis factor (TNF) family and it is
broadly expressed in immune cells, including macrophages.
CD40-activated macrophages are indicative of M1 pheno-
type correlating with reinforced proinflammatory cytokines
release as well as upregulated expression of antigen presen-
tation molecules such as major histocompatibility complex
(MHC)-II [152]. According to Robert H.’s study, the
administration of CD40 mAb in mice was able to induce
macrophage-dependent tumor regression [146]. The toler-
ance and activity of CP-870,893 either as a single agent or
in combination with chemotherapy have been tested in
several clinical trials. In the first-in-human study, a single
infusion of CP-870,893 was well tolerated at the 0.2 mg/
kg. Partial responses (PR) were achieved in four patients
with metastatic melanoma, and one of those four patients
remained in partial remission even at the 14th month
[126]. What is more, in patients with advanced PDAC,
CP-870,893 administration with gemcitabine was revealed
to induce an objective response rate (ORR) of 19% (4 in
23 patients developed a partial response), a median
progression-free survival (mPFS) of 5.6 months, and a me-
dian overall survival (OS) of 7.4 months, which are super-
ior to the historical efficacy of single gemcitabine in
PDAC (ORR of 5.4%, mPFS of 2.3 months, and mOS of
5.7 months) [127, 146]. Anyway, those clinical trials are
still at an early stage with small sample size [126, 127, 146,
153]. Further randomized clinical studies with larger sam-
ple size are definitely warranted to validate their potential
in clinical applications.
Agents inhibiting macrophages recruitment
As mentioned above, most of the TAMs originate from
the bone marrow monocyte procurers. Recruitment of
TAMs to the tumor sites or PMNs is a consequence of
the continuous presence of tumor-derived chemoattrac-
tants. Therefore, cutting off those attracting signals for
the macrophage recruitment appeals to be another
promising solution for TAMs targeting anti-cancer
therapeutic approach.
In addition to their roles in educating macrophages
into M2 phenotype, both CSF-1 and CCL2 are respon-
sible for recruiting TAMs into TME. It was reported that
both small molecular inhibitors and antibodies targeting
either CCL2/CCR2 or CSF-1/CSF-1R signaling axisobviously inhibited the mobilization of monocytes and
macrophages accumulation in tumor sites. As a matter
of fact, several inhibitors and antibodies targeting the
TAM recruiting factors are being evaluated in early clin-
ical trials across various types of tumor [132, 133, 154,
155]. For example, emactuzumab (RG7155) is a novel
humanized antibody targeting CSF-1R in both ligand-
dependent and ligand-independent manners [154]. Re-
searchers found that administration of RG7155 signifi-
cantly lowered the amount of CSF-1R expressing TAMs
in on-treatment biopsies from tumor lesions [154]. A
similar promising result has also been reported from
clinical achievements in diffuse-type giant cell tumor
(Dt-GCT), a neoplastic disorder characterized by CSF-1
overexpression and CSF-1R-positive TAM accumulation.
In this study, among the 28 patients totally enrolled, 24
cases (86%) achieved complete response (CR) or PR, and
three patients (11%) had stable disease (SD), with the
average duration of response over 1.9 years [129]. How-
ever, whether this inspiring result in Dt-GCT could be
carried over to other solid tumors remains a question
and requires further investigation. What is more, pexi-
dartinib (also known as PLX3397), an oral tyrosine kin-
ase inhibitor of CSF-1R, exhibited similar efficiency (PR
52%, SD 30%, progressive disease 4%) in Dt-GCT pa-
tients as what RG7155 exhibits [130]. However, the
phase II clinical trial showed no benefit from the admin-
istration of pexidartinib in 38 recurrent GBM patients
[130]. But it is still worth looking forward to the results
of many other ongoing clinical trials, which are con-
ducted in c-kit-mutated melanoma, prostate cancer, sar-
coma, and etc. [130]. Encouragingly, preliminary clinical
benefit has been observed in a phase Ib trial evaluating
the safety and effectiveness of CCX872, an orally admin-
istered CCR2 inhibitor, in patients with advanced pan-
creatic cancer. According to the data announced in
January 2018, 29% patients receiving CCX872 and FOL-
FIRINOX combination therapy survived at the 18th
month, more favorable than previously published OS
rates of 18.6% at 18th month using FOLFIRINOX alone
[132, 133]. Furthermore, a number of agents, such as
CCL2 inhibitor bindarit, anti-CCL2 mAb carlumab,
CSF1 inhibitor GW2580, and dequalinium-14, have been
confirmed of potent and sustained anti-tumor activities
via declining macrophages infiltration in a battery of cell
lines and xenograft models [156–160]. It is conceivable
that some of these agents will enter clinical trials in the
near future to be further evaluated for their safety pro-
files and benefits in patient cohorts [155].
Conclusions and perspectives
Cancer is more of a systemic disease since metastasis oc-
curs in the majority of patients. Effectiveness achieved
by existing therapeutics is far from satisfactory, since
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or interdict tumor cells themselves while the successful
outgrowth of metastases is largely influenced by non-
malignant cells of the tumor microenvironment (TME)
[5, 6, 82]. As the major orchesters of the TME, TAMs
tightly regulate tumor metastasis in all of the steps in-
volved. In this review, we discussed the implicated regula-
tion factors participating in recruitment and polarization
of TAMs. In specific, we detailedly described the under-
lying mechanisms for TAM-involved tumor metastasis.
When we get a better understanding of the correlation be-
tween TAMs and metastasis, the potential therapeutic
strategies targeting TAMs would display a promising pic-
ture for cancer intervention. Indeed, we believe that tar-
geting the pro-metastatic components of TME and
rebuilding a healthier microenvironment with a reborn
capacity to hamper tumor growth will definitely hold
promise for cancer therapy.
In the past decades, our mechanistic investigations of
TAMs never ceased and several TAM-targeted agents
are available nowadays. Although TAM-targeted therapy
based on modulation of TAM survival, polarization, and
recruitment is attracting more and more attention in
cancer prevention and treatment, there are many funda-
mental hurdles lying ahead before the findings of those
researches finally transmitted into clinical benefits.
Firstly, TAMs are endowed with remarkably
heterogenous roles in modulating metastasis. On the
one hand, while TAMs are conventionally acknowledged
as M2-like, they can, in fact, exhibit phenotypes any-
where in between tumoricidal M1 type and pro-tumoral
M2 type. How phenotypes switch over the course of
tumor progression is not fully known. On the other
hand, molecular and cell-biological details involved in
promoting metastasis might be more complicated than
what we expect. Various major points of regulation net-
works remain elusive. Therefore, it is of great necessity
for us to explore the unknown mechanisms underlying
TAM-facilitated metastasis and figure out more detailed
TAM characterizations as well as associated molecular
profiles in TME.
Secondly, in spite of inspiring preclinical data obtained
from numerous laboratories, the translational benefits of
agents targeting TAMs are somewhat not that satisfac-
tory in clinical studies. No agent has received official ap-
proval for clinical use of cancer treatment so far [161,
162]. There is an intriguing possibility that tumors with
different histological types and gradings, different gen-
etic background, as well as diverse local inflammatory
profiles, might have heterogenous responses to the same
treatment. Therefore, there arises the tip of a far larger
iceberg: what histology types or what cellular and mo-
lecular features in TME would benefit from TAM-
targeted therapy? The answer is pending. Furtherexplorations in both preclinical and clinical studies are
in desperate need. In clinical practice, pathology reports
do not routinely describe TAM features in tumor sam-
ples, making it difficult to identify potential TAM-target
beneficiaries and creating a gap in knowledge between
the clinic and tumor immunology research. Hence, figur-
ing out TAM-related features, such as amount, pheno-
types, and cytokine profiles on the pathology reports, or
even assessing circulating M2 macrophage numbers as
well as systemic CSF1, CCL2 levels might provide a tool
for better predicting cancer metastasis and stratifying
patients [158]. Furthermore, TAM-targeting therapies,
either by blocking their infiltration into TME or by
impairing pro-tumoral functions, are insufficient to
achieve satisfying metastasis control without a direct at-
tack on tumor cells. Approaches combining TAM-
targeting agents with chemotherapeutics, irradiation,
antiangiogenic agents, and immune checkpoint inhibi-
tors may pave the way for augmented control of progres-
sion and metastasis [163, 164]. But most of these
concerns have not been realized in a clinically significant
way. Further studies are warranted to evaluate their
therapeutic effectiveness both as a single agent or as part
of a combination therapy.
When we come to talk about the immune checkpoint
based therapy, it is worth noting that targeting immune
checkpoint pathways, such as the innate anti-phagocytic
axis of CD47-SIRPα (signal-regulatory protein alpha)
pathway and LILRB receptor pathway, is emerged as one
of most attractive strategy for cancer therapy. For ex-
ample, CD47 expressed in tumor cells can interact with
signal-regulatory protein alpha (SIRPα) which is a trans-
membrane protein on macrophage and the main receptor
of CD47, thereby delivering the “do not eat me” signals to
macrophages [165]. Studies found that the expression of
CD47 increases in various tumors to evade immune attack
[166]. Therefore, CD47-SIRPα interaction blockade by
anti-CD47 blocking antibody increased the infiltration of
macrophages in the TME, thus promoting phagocytosis of
CD47+ tumor cells to exert antitumor efficacy [167, 168].
Besides, the leukocyte immunoglobulin-like receptor B
(LILRB) family members are negative regulators of mye-
loid cell activation [169, 170]. Studies found that LILRB2
blockade by LILRB2-specific monoclonal antibodies ef-
fectively polarized macrophage cells toward an inflamma-
tory phenotype and enhanced pro-inflammatory
responses, thus acting as a myeloid immune checkpoint
by reprogramming TAMs and provoking antitumor im-
munity [171, 172].
Thirdly, noting that TAMs do not exert functions in
isolation, the TME is a complex system consists of a
plethora of cells other than TAMs, such as fibroblasts,
epitheliums, neutrophils, mesenchymal stem cells, mye-
loid cell-derived suppressor cells, and mast cells. They
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with each other constantly alongside the formation of
metastasis [117]. Preclinical experiments targeting
TAMs without the consideration of intricacy and versa-
tility in their interactions are prone to fail in arising ef-
fective therapeutic approaches in the clinic. Hence,
digging into the respective roles of those components of
TME and modeling their intricate interactions evolving
along with the metastasis by system biology approaches
may be the avenues for future research [162].
In conclusion, this review provides an overview of our
current understanding of the cross talk between TAMs
and tumor cells during tumor progression, particularly
in metastasis. As stated above, TAM represents a novel
and attractive target that may alter the landscape of fu-
ture cancer therapy, although many critical obstacles are
still lying ahead and more endeavors in this aspect are




YXL was involved in the drafting of the manuscript. HYL was involved in the
editing and revising of the manuscript critically for the important scientific
content. JXX was involved in the editing of the content and providing the
final approval of the version to be published. All authors read and approved
the final manuscript.
Funding
This work was supported by the Key Chinese Traditional Medicine Specialty
Project of Huzhou City (2016ZZ07).
Availability of data and materials
Not applicable.





The authors declare that they have no competing interests.
Author details
1Department of Oncology, Hospital of Chinese Medicine of Changxing
County, Huzhou 313100, China. 2Department of Radiation Oncology,
Zhejiang Key Lab of Radiation Oncology, Zhejiang Cancer Hospital,
Hangzhou, China. 3Division of Radiation and Cancer Biology, Department of
Radiation Oncology, University of Michigan, MS-1, 1301 Catherine Street, Ann
Arbor, MI 48109, USA.
Received: 17 March 2019 Accepted: 25 June 2019
References
1. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev
Oncog. 2013;18(1-2):43–73.
2. Scully OJ, Bay BH, Yip G, Yu YN. Breast cancer metastasis. Cancer Genomics
Proteomics. 2012;9(5):311–20.
3. Fidler IJ, Kripke ML. The challenge of targeting metastasis. Cancer Metastasis
Rev. 2015;34(4):635–41.
4. Paget S. The distribution of secondary growths in cancer of the breast.
1889. Cancer Metastasis Rev. 1989;8(2):98–101.5. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression
and metastasis. Nat Med. 2013;19(11):1423–37.
6. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a
critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;
16(8):717–27.
7. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in
the tumor microenvironment. Trends Immunol. 2012;33(3):119–26.
8. Singh S, Mehta N, Lilan J, Budhthoki MB, Chao F, Yong L. Initiative action of tumor-
associated macrophage during tumor metastasis. Biochimie Open. 2017;4:8–18.
9. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage
heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1–8.
10. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer.
Cancer Cell. 2015;27(4):462–72.
11. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development,
homeostasis and disease. Nature. 2013;496(7446):445–55.
12. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor
microenvironments. Cancer Res. 2006;66(2):605–12.
13. Pollard JW. Macrophages define the invasive microenvironment in breast
cancer. J Leukoc Biol. 2008;84(3):623–30.
14. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG, Li MO.
The cellular and molecular origin of tumor-associated macrophages.
Science. 2014;344(6186):921–5.
15. Shand FHW, Ueha S, Otsuji M, Koid SS, Shichino S, Tsukui T, Kosugi-Kanaya
M, Abe J, Tomura M, Ziogas J, Matsushima K. Tracking of intertissue
migration reveals the origins of tumor-infiltrating monocytes. Proc Natl
Acad Sci U S A. 2014;111(21):7771–6.
16. Liu Y, Cao XT. The origin and function of tumor-associated macrophages.
Cell Mol Immunol. 2015;12:1.
17. Bain CC, Scott CL, Mowat AM. Resident and pro-inflammatory macrophages
in the colon represent alternative context dependent fates of the same
Ly6Chi monocyte precursors. Immunology. 2012;137:218.
18. Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K,
Prinz M, Wu BS, Jacobsen SEW, Pollard JW, Frampton J, Liu KJ, Geissmann F.
A lineage of myeloid cells independent of Myb and hematopoietic stem
cells. Science. 2012;336(6077):86–90.
19. Sharma SK, Chintala NK, Vadrevu SK, Patel J, Karbowniczek M, Markiewski
MM. Pulmonary alveolar macrophages contribute to the premetastatic
niche by suppressing antitumor T cell responses in the lungs. J Immunol.
2015;194(11):5529–38.
20. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi
K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M,
Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G,
Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-
17-mediated tumour growth. Nature. 2012;491(7423):254–8.
21. Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in
monocytes/macrophages suppresses the initiation of hepatocellular
carcinoma in mice. J Exp Clin Cancer Res. 2016;35(1):131.
22. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E,
Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA.
Tumor-associated macrophages in breast cancer: distinct subsets, distinct
functions. Int J Dev Biol. 2011;55(7-9):861–7.
23. Biswas SK, Mantovani A. Macrophage plasticity and interaction with
lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.
24. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and
metastasis. Cell. 2010;141(1):39–51.
25. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J,
Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different
tumor microenvironments contain functionally distinct subsets of macrophages
derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728–39.
26. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage
polarization: tumor-associated macrophages as a paradigm for polarized M2
mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.
27. Zhang MY, He YF, Sun XJ, Li Q, Wang WJ, Zhao AM, Di W. A high M1/M2
ratio of tumor-associated macrophages is associated with extended survival
in ovarian cancer patients. J Ovarian Res. 2014;7:19.
28. Henze AT, Mazzone M. The impact of hypoxia on tumor-associated
macrophages. J Clin Invest. 2016;126(10):3672–9.
29. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, Nishimura M,
Yoshida J, Takeyoshi I, Ochiai A. Stromal macrophage expressing CD204 is
associated with tumor aggressiveness in lung adenocarcinoma. J Thorac
Oncol. 2010;5(10):1507–15.
Lin et al. Journal of Hematology & Oncology           (2019) 12:76 Page 13 of 1630. Sawa-Wejksza K, Kandefer-Szerszen M. Tumor-associated macrophages
as target for antitumor therapy. Arch Immunol Ther Exp (Warsz). 2018;
66(2):97–111.
31. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor
progression. Cancer Metastasis Rev. 2007;26(3-4):717–24.
32. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P,
Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4
expression identifies a novel suppressive macrophage population in human
ovarian carcinoma. J Exp Med. 2006;203(4):871–81.
33. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a
leading role for STAT3. Nature Rev Cancer. 2009;9(11):798–809.
34. Murray PJ, Wynn TA. Obstacles and opportunities for understanding
macrophage polarization. J Leukoc Biol. 2011;89(4):557–63.
35. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor
associated macrophages in human cancers. J Translat Med. 2011;9:216.
36. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling
of the human monocyte-to-macrophage differentiation and polarization:
New molecules and patterns of gene expression. J Immunol. 2006;
177(10):7303–11.
37. Verreck FAW, de Boer T, Langenberg DML, van der Zanden L, Ottenhoff
THM. Phenotypic and functional profiling of human proinflammatory type-1
and anti-inflammatory type-2 macrophages in response to microbial
antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc
Biol. 2006;79(2):285–93.
38. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A,
Mantovani A, Mordoh J, Wainstok R. Targeting tumor-associated
macrophages and inhibition of MCP-1 reduce angiogenesis and tumor
growth in a human melanoma xenograft. J Investig Dermatol. 2007;127(8):
2031–41.
39. Qian BZ, Li JF, Zhang H, Kitamura T, Zhang JH, Campion LR, Kaiser EA,
Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate
breast-tumour metastasis. Nature. 2011;475(7355):222–U129.
40. Sierra-Filardi E, Nieto C, Dominguez-Soto A, Barroso R, Sanchez-Mateos P,
Puig-Kroger A, Lopez-Bravo M, Joven J, Ardavin C, Rodriguez-Fernandez JL,
Sanchez-Torres C, Mellado M, Corbi AL. CCL2 Shapes macrophage
polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent
gene expression profile. J Immunol. 2014;192(8):3858–67.
41. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS,
Roca H, Pienta KJ. The chemokine CCL2 increases prostate tumor growth
and bone metastasis through macrophage and osteoclast recruitmenT.
Neoplasia. 2009;11(11):1235–42.
42. Abraham D, Zins K, Sioud M, Lucas T, Schafer R, Stanley ER, Aharinejad S.
Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-
negative neuroblastoma. Int J Cancer. 2010;126(6):1339–52.
43. Hume DA, MacDonald KPA. Therapeutic applications of macrophage
colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-
1R) signaling. Blood. 2012;119(8):1810–20.
44. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine
Netw. 2009;20(4):158–63.
45. Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, Mueller MM.
Vascular endothelial growth factor-induced skin carcinogenesis depends on
recruitment and alternative activation of macrophages. J Pathol. 2012;227(1):
17–28.
46. Lin EY, Li J-F, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, Pollard JW.
Vascular endothelial growth factor restores delayed tumor progression in
tumors depleted of macrophages. Mol Oncol. 2007;1(3):288–302.
47. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D’Amore
PA, Dana MR, Wiegand SJ, Streilein JW. VEGF-A stimulates
lymphangiogenesis and hemangiogenesis in inflammatory
neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7):
1040–50.
48. Yuxin Lin XW, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and
strategies. Am J Cancer Res. 2014;4(4):411–35.
49. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK,
Hammer M, Zenz R, Peck-Radosavljevic M, Sieghart W, Trauner M, Wang H,
Sibilia M. EGFR has a tumour-promoting role in liver macrophages during
hepatocellular carcinoma formation. Nat Cell Biol. 2014;16(10):972–7.
50. Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, Gobert AP,
Piazuelo MB, Washington MK, Wilson KT. EGFR-mediated macrophage
activation promotes colitis-associated tumorigenesis. Oncogene. 2017;
36(27):3807–19.51. Ma XY, Wu DQ, Zhou S, Wan F, Liu H, Xu XR, Xu XF, Zhao Y, Tang MC. The
pancreatic cancer secreted REG4 promotes macrophage polarization to M2
through EGFR/AKT/CREB pathway. Oncol Rep. 2016;35(1):189–96.
52. Zhang WN, Chen LC, Ma K, Zhao YH, Liu XH, Wang Y, Liu M, Liang SF, Zhu
HX, Xu NZ. Polarization of macrophages in the tumor microenvironment is
influenced by EGFR signaling within colon cancer cells. Oncotarget. 2016;
7(46):75366–78.
53. Digiacomo G, Ziche M, Dello Sbarba P, Donnini S, Rovida E.
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor
and synergizes with colony-stimulating factor-1 in the induction of
macrophage migration via the mitogen-activated protein kinase ERK1/2.
FASEB J. 2015;29(6):2545–54.
54. Chen PC, Cheng HC, Wang J, Wang SW, Tai HC, Lin CW, Tang CH. Prostate
cancer-derived CCN3 induces M2 macrophage infiltration and contributes
to angiogenesis in prostate cancer microenvironment. Oncotarget. 2014;
5(6):1595–608.
55. Jeannin P, Duluc D, Delneste Y. IL-6 and leukemia-inhibitory factor are
involved in the generation of tumor-associated macrophage: regulation by
IFN-gamma. Immunotherapy. 2011;3(4):23–6.
56. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to
therapy. Immunity. 2014;41(1):49–61.
57. Ding HX, Zhao LM, Dai SL, Li L, Wang FJ, Shan BE. CCL5 secreted by tumor
associated macrophages may be a new target in treatment of gastric
cancer. Biomed Pharmacother. 2016;77:142–9.
58. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory
mechanisms, and cellular response. Oncologist. 2004;9:4–9.
59. Chae YC, Vaira V, Caino MC, Tang HY, Seo JH, Kossenkov AV, Ottobrini L,
Martelli C, Lucignani G, Bertolini I, Locatelli M, Bryant KG, Ghosh JC, Lisanti S,
Ku B, Bosari S, Languino LR, Speicher DW, Altieri DC. Mitochondrial Akt
regulation of hypoxic tumor reprogramming. Cancer Cell. 2016;30(2):257–72.
60. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, Graham
CH. Hypoxia induces escape from innate immunity in cancer cells via
increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011;
71(24):7433–41.
61. Zhang CC, Sadek HA. Hypoxia and metabolic properties of hematopoietic
stem cells. Antioxid Redox Signal. 2014;20(12):1891–901.
62. Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei P,
LaRosa G, Scotton C, Balkwill F, Mantovani A. Defective expression of the
monocyte chemotactic protein-1 receptor CCR2 in macrophages associated
with human ovarian carcinoma. J Immunol. 2000;164(2):733–8.
63. Bosco MC, Reffo G, Puppo M, Varesio L. Hypoxia inhibits the expression of the
CCR5 chemokine receptor in macrophages. Cell Immunol. 2004;228(1):1–7.
64. Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, Siegwart DJ, Wan
Y. Gpr132 sensing of lactate mediates tumor-macrophage interplay to
promote breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114(3):
580–5.
65. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human
monocytes and their responses to angiopoietin-2. J Immunol. 2007;178(11):
7405–11.
66. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R,
Doglioni C, Naldini L. Identification of proangiogenic TIE2-expressing
monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;
109(12):5276–85.
67. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y,
Movahedi K, Houbracken I, Schouppe E, Elkrim Y, Karroum O, Jordan B,
Carmeliet P, Gysemans C, De Baetselier P, Mazzone M, Van Ginderachter JA.
Tumor hypoxia does not drive differentiation of tumor-associated
macrophages but rather fine-tunes the M2-like macrophage population.
Cancer Res. 2014;74(1):24–30.
68. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;
31(1):27–36.
69. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and
clinical perspective. Semin Reprod Med. 2009;27(5):351–7.
70. Hoeksema MA, de Winther MPJ. Epigenetic regulation of monocyte and
macrophage function. Antioxid Redox Signal. 2016;25(14):758–74.
71. Kapellos TS, Iqbal AJ. Epigenetic control of macrophage polarisation and
soluble mediator gene expression during inflammation. Mediators
Inflamma. 2016;2016:6591703.
72. Squadrito ML, Etzrodt M, De Palma M, Pittet MJ. MicroRNA-mediated
control of macrophages and its implications for cancer. Trends Immunol.
2013;34(7):350–9.
Lin et al. Journal of Hematology & Oncology           (2019) 12:76 Page 14 of 1673. Ying X, Wu QF, Wu XL, Zhu QY, Wang XJ, Jiang L, Chen X, Wang XP.
Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization
of tumor-associated macrophages. Oncotarget. 2016;7(28):43076–87.
74. Wang Z, Xu L, Hu Y, Huang Y, Zhang Y, Zheng X, Wang S, Wang Y, Yu Y,
Zhang M, Yuan K, Min W. miRNA let-7b modulates macrophage polarization
and enhances tumor-associated macrophages to promote angiogenesis
and mobility in prostate cancer. Sci Rep. 2016;6:25602.
75. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;
127(4):679–95.
76. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann
Oncol. 2010;21(Suppl 7):vii89–92.
77. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.
78. Moustakas A, Heldin CH. Signaling networks guiding epithelial-
mesenchymal transitions during embryogenesis and cancer progression.
Cancer Sci. 2007;98(10):1512–20.
79. Su SC, Liu Q, Chen JQ, Chen JN, Chen F, He CH, Huang D, Wu W, Lin L, Huang
W, Zhang J, Cui XY, Zheng F, Li HY, Yao HR, Su FX, Song EW. A positive
feedback loop between Mesenchymal-like cancer cells and macrophages is
essential to breast cancer metastasis. Cancer Cell. 2014;25(5):605–20.
80. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, Zhao YM, Xiao YS, Sun
QM, Ding ZB, Fan J. Macrophage-secreted IL-8 induces-epithelial-
mesenchymal transition in hepatocellular carcinoma cells by activating the
JAK2/STAT3/Snail pathway. Int J Oncol. 2015;46(2):587–96.
81. Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK. Cannabinoid receptor-2
agonist inhibits macrophage induced EMT in non-small cell lung cancer by
downregulation of EGFR pathway. Mol Carcinog. 2016;55(12):2063–76.
82. Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren H, Vogel I,
Kruger U, Becker T, Ebsen M, Rocken C, Kabelitz D, Schafer H, Sebens S.
Tumor-associated macrophages exhibit pro- and anti-inflammatory
properties by which they impact on pancreatic tumorigenesis. Int J Cancer.
2014;135(4):843–61.
83. Wu Y, Deng J, Rychahou PG, Qiu SM, Evers BM, Zhou BPH. Stabilization of
Snail by NF-kappa B Is required for inflammation-induced cell migration and
invasion. Cancer Cell. 2009;15(5):416–28.
84. Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, Watabe T, Miyazono
K. TGF-beta-induced epithelial-mesenchymal transition of A549 lung
adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived
from RAW 264.7 macrophage cells. J Biochem. 2012;151(2):205–16.
85. Chambers DBJGA. Extracellular matrix: a gatekeeper in the transition from
dormancy to metastatic growth. Eur J Cancer. 2010;46(7):1181–8.
86. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell. 2010;141(1):52–67.
87. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J,
Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C, Reinheckel T. Tumor
cell-derived and macrophage-derived cathepsin B promotes progression
and lung metastasis of mammary cancer. Cancer Res. 2006;66(10):5242–50.
88. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T,
Joyce JA. IL-4 induces cathepsin protease activity in tumor-associated
macrophages to promote cancer growth and invasion. Genes Dev. 2010;
24(3):241–55.
89. Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages
promote gastric and breast cancer metastasis via M2 macrophage-secreted
CHI3L1 protein. J Hematol Oncol. 2017;10(1):36.
90. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, Rumio
C, Brekken RA, Chiodoni C, Colombo MP. Macrophage-derived SPARC
bridges tumor cell-extracellular matrix interactions toward metastasis.
Cancer Res. 2008;68(21):9050–9.
91. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat
Rev Cancer. 2003;3(12):921–30.
92. Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM,
Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH. SPARC
regulates extracellular matrix organization through its modulation of
integrin-linked kinase activity. J Biol Chem. 2005;280(43):36483–93.
93. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH.
Enhanced growth of tumors in SPARC null mice is associated with changes
in the ECM. J Clin Invest. 2003;111(4):487–95.
94. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of
tumour angiogenesis: The angiogenic switch, its molecular controls, and
prospects for preclinical therapeutic models. Eur J Cancer. 1996;32a(14):
2386–93.95. Metcalf S, Pandha HS, Morgan R. Antiangiogenic effects of zoledronate on
cancer neovasculature. Future Oncol. 2011;7(11):1325–33.
96. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN,
Pollard JW. Macrophages regulate the angiogenic switch in a mouse model
of breast cancer. Cancer Res. 2006;66(23):11238–46.
97. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic
switch in breast cancer. Cancer Res. 2007;67(11):5064–6.
98. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe
P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the
angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737–44.
99. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-
expressing macrophages and angiogenesis to impair cervical
carcinogenesis. J Clin Invest. 2004;114(5):623–33.
100. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, Miyazaki
M, Sakakibara M, Hiramatsu N, Kasahara A, Tomimaru Y, Tomokuni A,
Nagano H, Hayashi N, Takehara T. TIE2-expressing monocytes as a
diagnostic marker for hepatocellular carcinoma correlates with
angiogenesis. Hepatology. 2013;57(4):1416–25.
101. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role
of tumor associated macrophages in tumor angiogenesis and
lymphangiogenesis. Front Physiol. 2014;5:75.
102. Cao RH, Ji H, Yang YL, Cao YH. Collaborative effects between the TNF alpha-
TNFR1-macrophage axis and the VEGF-C-VEGFR3 signaling in
lymphangiogenesis and metastasis. Oncoimmunology. 2015;4:3.
103. Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD,
Raviv Z, Merquiol E, Ben-Nun Y, Miller V, Rachman-Tzemah C, Timaner M,
Mumblat Y, Ilan N, Loven D, Hershkovitz D, Satchi-Fainaro R, Blum G,
Sleeman JP, Vlodavsky I, Shaked Y. Macrophage-induced lymphangiogenesis
and metastasis following paclitaxel chemotherapy is regulated by VEGFR3.
Cell Rep. 2016;17(5):1344–56.
104. Wyckoff JB, Jones JG, Condeelis JS, Segall JE. A critical step in metastasis:
in vivo analysis of intravasation at the primary tumor. Cancer Res. 2000;60(9):
2504–11.
105. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard
JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell
intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–56.
106. Wang J, Cao Z, Zhang XM, Nakamura M, Sun M, Hartman J, Harris RA, Sun Y,
Cao Y. Novel mechanism of macrophage-mediated metastasis revealed in a
zebrafish model of tumor development. Cancer Res. 2015;75(2):306–15.
107. Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG.
Tumor microenvironment of metastasis in human breast carcinoma: a
potential prognostic marker linked to hematogenous dissemination. Clin
Cancer Res. 2009;15(7):2433–41.
108. Wyckoff J, Wang WG, Lin EY, Wang YR, Pixley F, Stanley ER, Graf T, Pollard
JW, Segall J, Condeelis J. A paracrine loop between tumor cells and
macrophages is required for tumor cell migration in mammary tumors.
Cancer Res. 2004;64(19):7022–9.
109. Goswami S, Sahai E, Wyckoff JB, Cammer N, Cox D, Pixley FJ, Stanley ER,
Segall JE, Condeelis JS. Macrophages promote the invasion of breast
carcinoma cells via a colony-stimulating factor-1/epidermal growth factor
paracrine loop. Cancer Res. 2005;65(12):5278–83.
110. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and
angiogenesis: Evidence for a thrombin-regulated dormant tumor
phenotype. Cancer Cell. 2006;10(5):355–62.
111. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck
KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and
circulating hemostatic factors cooperate to increase metastatic potential
through natural killer cell-dependent and-independent mechanisms. Blood.
2007;110(1):133–41.
112. Gil-Bernabe AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, Im JH, Watson K, Hill
SA, Amirkhosravi A, Francis JL, Pollard JW, Ruf W, Muschel RJ. Recruitment of
monocytes/macrophages by tissue factor-mediated coagulation is essential
for metastatic cell survival and premetastatic niche establishment in mice.
Blood. 2012;119(13):3164–75.
113. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1
transmits survival signals in breast cancer cells that invade the lungs. Cancer
Cell. 2011;20(4):538–49.
114. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X,
Haffty BG, Pantel K, Massague J, Kang Y. VCAM-1 promotes osteolytic
expansion of indolent bone micrometastasis of breast cancer by engaging
alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701–14.
Lin et al. Journal of Hematology & Oncology           (2019) 12:76 Page 15 of 16115. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW. A
distinct macrophage population mediates metastatic breast cancer cell
extravasation, establishment and growth. PLoS One. 2009;4(8):e6562.
116. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,
MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu ZP, Hicklin D, Wu Y, Port JL,
Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D.
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-
metastatic niche. Nature. 2005;438(7069):820–7.
117. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev
Cancer. 2009;9(4):239–52.
118. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common
ground. Cancer Metastasis Rev. 2013;32(3-4):449–64.
119. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic
niche’: within bone and beyond. Cancer Metastasis Rev. 2006;25(4):521–9.
120. Lu X, Kang YB. Organotropism of breast cancer metastasis. J Mammary
Gland Biol Neoplasia. 2007;12(2-3):153–62.
121. Muller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A.
Involvement of chemokine receptors in breast cancer metastasis. Nature.
2001;410(6824):50–6.
122. Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita ASM,
Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-
human phase I study of lurbinectedin (PM01183) in patients with advanced
solid tumors. Clin Cancer Res. 2014;20(8):2205–14.
123. Poveda A, del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Alia
EMG, Casado A, Gonzalez-Martin A, Fernandez C, Rodriguez I, Soto A, Kahatt
C, Teruel CF, Galmarini CM, de la Haza AP, Bohan P, Berton-Rigaud D. Phase
II randomized study of PM01183 versus topotecan in patients with
platinum-resistant/refractory advanced ovarian cancer. Ann Oncol. 2017;
28(6):1280–7.
124. Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A,
Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E. Phase I clinical and
pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin)
in combination with gemcitabine in patients with advanced solid tumors.
Invest New Drugs. 2017;35(2):198–206.
125. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C,
Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H,
Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP,
Fesl C, Greil R, Austrian B, Colorectal Cancer Study Group VA. Adjuvant
endocrine therapy plus zoledronic acid in premenopausal women with
early-stage breast cancer: 62-month follow-up from the ABCSG-12
randomised trial. Lancet Oncol. 2011;12(7):631–41.
126. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA,
Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ,
Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation
in cancer patients treated with CP-870,893, a novel CD40 agonist
monoclonal antibody. J Clin Oncol. 2007;25(7):876–83.
127. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel
AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of
an agonist CD40 monoclonal antibody (CP-870,893) in combination with
gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Clin Cancer Res. 2013;19(22):6286–95.
128. Gomez-Roca CA, Cassier PA, Italiano A, Cannarile M, Ries C, Brillouet A,
Mueller C, Jegg AM, Meneses-Lorente G, Baehner M, Abiraj K, Loirat D,
Toulmonde M, D'Angelo SP, Weber K, Campone M, Ruettinger D, Blay JY,
Delord JP, Le Tourneau C. Phase I study of RG7155, a novel anti-CSF1R
antibody, in patients with advanced/metastatic solid tumors. J Clin Oncol.
2015;33:15.
129. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud
F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich
S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C,
de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY,
Ruttinger D. Targeting tumor-associated macrophages with anti-CSF-1R
antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):
846–59.
130. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY,
Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL,
Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered
colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent
glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase
II study. Neuro Oncol. 2016;18(4):557–64.131. Bendell JC, Tolcher AW, Jones SF, Beeram M, Infante JR, Larsen P, Rasor K,
Garrus JE, Li JF, Cable PL, Eberhardt C, Schreiber J, Rush S, Wood KW, Barret
E, Patnaik A. A phase 1 study of ARRY-382, an oral inhibitor of colony-
stimulating factor-1 receptor (CSF1R), in patients with advanced or
metastatic cancers. Mol Cancer Ther. 2013;12:11.
132. Noel MS, Hezel AF, Linehan D, Wang-Gillam A, Eskens F, Sleijfer S,
Desar I, Erdkamp F, Wilmink J, Diehl J, Potarca A, Zhao N, Deng J, Lohr
L, Miao SC, Charo I, Singh R, Schall TJ, Bekker P. Orally administered
CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. J
Clin Oncol. 2017;35:4.
133. Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, Desar IM,
Erdkamp F, Wilmink J, Diehl J, Potarca A, Zhao N, Miao S, Deng J, Hillson J,
Bekker P, Schall TJ, Singh R. Overall survival in a trial of orally administered
CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer:
Correlation with blood monocyte counts. J Clin Oncol. 2018;36:5.
134. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM,
Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R,
Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DG DN,
Goedegebuure SP, Linehan DC. Targeting tumour-associated macrophages
with CCR2 inhibition in combination with FOLFIRINOX in patients with
borderline resectable and locally advanced pancreatic cancer: a single-
centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet
Oncol. 2016;17(5):651–62.
135. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to
clinical application. J Hematol Oncol. 2017;10(1):58.
136. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E,
Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R,
Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S,
Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of
macrophage targeting in the antitumor activity of trabectedin. Cancer Cell.
2013;23(2):249–62.
137. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique
mechanism of action. Mol Cancer Ther. 2010;9(8):2157–63.
138. D'Incalci M. Trabectedin mechanism of action: what’s new? Future Oncol.
2013;9(12):5–10.
139. Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L,
Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P,
D’Incalci M. Lurbinectedin reduces tumour-associated macrophages and the
inflammatory tumour microenvironment in preclinical models. Br J Cancer.
2017;117(5):628–38.
140. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev
Immunol. 2005;5(12):953–64.
141. Cespedes MV, Guillen MJ, Lopez-Casas PP, Sarno F, Gallardo A, Alamo P,
Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Aviles P, Mangues R.
Lurbinectedin induces depletion of tumor-associated macrophages, an
essential component of its in vivo synergism with gemcitabine, in
pancreatic adenocarcinoma mouse models. Dis Model Mech. 2016;9(12):
1461–71.
142. Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Criado MPL, Kahatt C,
Lopez-Vilarino JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Matos-
Pita AS, Forster M. Antitumor activity of lurbinectedin (PM01183) and
doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Ann Oncol. 2017;28(10):2559–66.
143. Cieslewicz M, Tang J, Yu JL, Cao H, Zavaljevski M, Motoyama K, Lieber A,
Raines EW, Pun SH. Targeted delivery of proapoptotic peptides to tumor-
associated macrophages improves survival. Proc Natl Acad Sci U S A. 2013;
110(40):15919–24.
144. Ngambenjawong C, Cieslewicz M, Schellinger JG, Pun SH. Synthesis and
evaluation of multivalent M2pep peptides for targeting alternatively
activated M2 macrophages. J Control Release. 2016;224:103–11.
145. Kakoschky B, Pleli T, Schmithals C, Zeuzem S, Brune B, Vogl TJ, Korf HW,
Weigert A, Piiper A. Selective targeting of tumor associated macrophages in
different tumor models. PLoS One. 2018;13(2):e0193015.
146. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W,
Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ, Vonderheide RH.
CD40 agonists alter tumor stroma and show efficacy against pancreatic
carcinoma in mice and humans. Science. 2011;331(6024):1612–6.
147. Comito G, Segura CP, Sobierajska K, Ippolito L, Taddei ML, Giannoni E,
Chiarugi P. Zoledronic acid impairs stromal reactivity by inhibiting M2-
macrophages polarization and prostate cancer-associated fibroblasts. Eur J
Cancer. 2014;50:S74.
Lin et al. Journal of Hematology & Oncology           (2019) 12:76 Page 16 of 16148. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I,
Monkkonen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia
M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits
mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol
Med. 2010;14(12):2803–15.
149. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD,
Holen I. Macrophages as potential targets for zoledronic acid outside the
skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr).
2013;36(6):505–14.
150. Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL. CD40
immunotherapy for pancreatic cancer. Cancer Immunol Immunother. 2013;
62(5):949–54.
151. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer
therapy. Clin Cancer Res. 2007;13(4):1083–8.
152. Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of
disease protection and pathogenesis. Semin Immunol. 2009;21(5):257–64.
153. Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ,
Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA.
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in
combination with cisplatin and pemetrexed in malignant pleural
mesothelioma. Ann Oncol. 2015;26(12):2483–90.
154. Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Ruttinger D, Ries CH.
Macrophage susceptibility to emactuzumab (RG7155) treatment. Mol Cancer
Ther. 2016;15(12):3077–86.
155. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-
stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J
Immunother Cancer. 2017;5:53.
156. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon
DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L. Targeting
distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor:
combating tumor evasion of antiangiogenic therapy. Blood. 2010;115(7):
1461–71.
157. Steiner JL, Davis JM, McClellan JL, Guglielmotti A, Murphy EA. Effects of the
MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory
markers in the C3(1)/SV40Tag mouse model of breast cancer. Cytokine.
2014;66(1):60–8.
158. Swierczak A, Cook AD, Lenzo JC, Restall CM, Doherty JP, Anderson RL,
Hamilton JA. The promotion of breast cancer metastasis caused by
inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF
receptor. Cancer Immunol Res. 2014;2(8):765–76.
159. Moughon DL, He HH, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C,
Iruela-Arispe ML, Dorigo O, Wu L. Macrophage blockade using CSF1R
inhibitors reverses the vascular leakage underlying malignant ascites in late-
stage epithelial ovarian cancer. Cancer Res. 2015;75(22):4742–52.
160. Timaner M, Bril R, Kaidar-Person O, Rachman-Tzemah C, Alishekevitz D,
Kotsofruk R, Miller V, Nevelsky A, Daniel S, Raviv Z, Rotenberg SA, Shaked Y.
Dequalinium blocks macrophage-induced metastasis following local
radiation. Oncotarget. 2015;6(29):27537–54.
161. Keklikoglou I, De Palma M. Cancer: metastasis risk after anti-macrophage
therapy. Nature. 2014;515(7525):46–7.
162. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj
M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by
promoting angiogenesis. Nature. 2014;515(7525):130–3.
163. Torres-Collado SPJSZSJBA. Targeting distinct tumor-infiltrating myeloid cells
by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic
therapy. Blood. 2010;115(7):1461.
164. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W,
Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells
and improves the efficacy of radiotherapy in prostate cancer. Cancer Res.
2013;73(9):2782–94.
165. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRP alpha axis. Eur
J Cancer. 2017;76:100–9.
166. Liu XJ, Kwon H, Li ZH, Fu YX. Is CD47 an innate immune checkpoint for
tumor evasion? J Hematol Oncol. 2017;10:12.
167. Gu SL, Ni T, Wang J, Liu Y, Fan Q, Wang YW, Huang T, Chu YW, Sun X,
Wang YD. CD47 blockade inhibits tumor progression through promoting
phagocytosis of tumor cells by M2 polarized macrophages in endometrial
cancer. J Immunol Res. 2018;2018:6156757.
168. Alvey C, Discher DE. Engineering macrophages to eat cancer: from “marker
of self” CD47 and phagocytosis to differentiation. J Leukoc Biol. 2017;102(1):
31–40.169. Ma G, Pan PY, Eisenstein S, Divino CM, Lowell CA, Takai T, Chen SH. Paired
immunoglobin-like receptor-B regulates the suppressive function and fate
of myeloid-derived suppressor cells. Immunity. 2011;34(3):385–95.
170. van der Touw W, Chen HM, Pan PY, Chen SH. LILRB receptor-mediated
regulation of myeloid cell maturation and function. Cancer Immunol
Immunother. 2017;66(8):1079–87.
171. Zhang J, Mai S, Chen HM, Kang K, Li XC, Chen SH, Pan PY. Leukocyte
immunoglobulin-like receptors in human diseases: an overview of their
distribution, function, and potential application for immunotherapies. J
Leukoc Biol. 2017;102(2):351–60.
172. Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang JL, Alsina-
Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R,
Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH.
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated
myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128(12):
5647–62.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
